Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.31 - $1.06 $1,333 - $4,558
4,300 Added 14.1%
34,800 $27,000
Q4 2022

Feb 14, 2023

SELL
$0.27 - $11.9 $4,644 - $204,680
-17,200 Reduced 36.06%
30,500 $9,000
Q3 2022

Nov 14, 2022

BUY
$0.51 - $10.4 $1,173 - $23,920
2,300 Added 5.07%
47,700 $24,000

About Hepion Pharmaceuticals, Inc.


  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $51.8M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.